Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Pembrolizumab (MK-3475) in Patients With Recurrent Malignant Glioma With a Hypermutator Phenotype	Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, epithelial neoplasm, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor	Active, not recruiting	Not applicable	2026-08-20		NCT02658279

8 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Dana-Farber Cancer Institute	324
Huntsman Cancer Institute	21
M.D. Anderson Cancer Center	1145
Memorial Sloan Kettering Cancer Center	753
Merck Sharp & Dohme LLC	650
University of California, Los Angeles	355
University of California, San Francisco	637
University of Miami	277

16 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Brigham and Women's Hospital	Boston	United States	511
Cleveland Clinic	Cleveland	United States	558
Dana Farber Cancer Institute	Boston	United States	133
Massachusetts General Hospital	Boston	United States	1015
MD Anderson Cancer Center	Houston	United States	589
Memorial Sloan Kettering Bergen	Montvale	United States	193
Memorial Sloan Kettering Cancer Center	Basking Ridge	United States	12
Memorial Sloan Kettering Cancer Center	New York	United States	1000
Memorial Sloan Kettering Commack	Commack	United States	189
Memorial Sloan Kettering Monmouth	Middletown	United States	206
Memorial Sloan Kettering Nassau	Uniondale	United States	193
Memorial Sloan Kettering Westchester	East White Plains	United States	24
University of California San Francisco	San Francisco	United States	144
University of California, Los Angeles	Los Angeles	United States	142
University of Miami	Miami	United States	6
University of Utah	Salt Lake City	United States	137